MAP1LC3A and metabolic dysfunction-associated steatotic liver disease: Phloretin effectively attenuates the development of NAFLD by upregulating autophagy-mediated lipolysis, and the activation of autophagy is mainly manifested by decreasing the expression of SQSTM1/P62 and increasing the expression of Beclin1, Atg7, LC3 II/I, and Atg5 in liver tissues (44).